FIG. 1: It is possible to observe in the HAIROID ™️ the dermal papila, hair matrix, outer and inner root sheath and hair shaft [hematoxylin eosin staining].
Our main focus is to produce, autologous and allogeneic, hypoimmunogenic GENE EDITED hair-follicles for hair-loss treatment in clinics and transplantation into the human scalp.
With it’s patent filed high-tech 3D stem cell merger technology INVITROHAIR, a spin-off from an EUROPEAN CONTRACT RESEARCH ORGANISATION, performs its own development-equivalent to pharmaceutical and cosmetics companies - in the drug discovery and preclinical testing phase, to increase their efficiency and the success rate of compounds that pass the clinical trials, i.e. enhanced relevance.
Here we focus on ALOPECIA diseases, the performance of higly sophisticated tissue (hair)-engineering and Insilico computerial screening technologies .
Prior to the transplantation of bioengineered Hairfollicles we will provide to patients cell viability/proliferation assays, DERMAL PAPILLAE isolation, HAIR BULGE STEM CELL isolation, IPSC reprogramming, tissue engineering and cryogenic storage.For developers of STEMCELL THERAPIES we will provide our patent protected hypoimmunogenic Dermal Papillae cells- in order to contribute to the development of STEMCELL THERAPIES FOR ALOPECIA. THOSE METHODS CAN BE APPLIED TO ALREADY PRODUCED CELL LINES.
The approach requires intensive identification of pathogenic conditions and the precise identification of specific phenotypes.
We're following the P4 MEDICINE PRINCIPLES.
FIG. 2: migration from the attached DP
FIG. 3: Organoid merged. 92 days old
FIG. 4: de novo human hairfollicle prototype fixed in 4% PFA. Based on our US- PCT
FIG. 5: Printing of HAIROID ™️ upscale production test on biodegradable supportive grid